title: Philadelphia chromosome-positive acute myeloid leukemia with tetraploidy.
abstract: The patient was a 62-year-old man. His hematological data in April 2000 had shown no abnormalities, but he was referred to our hospital because of a fever and leukocytosis in June 2000. The peripheral blood showed 29.8 x 10(9)/L white blood cells, with 68.0% blasts. A bone marrow aspirate showed hypercellularity with a proliferation of large leukemic blasts. The leukemic cells were positive for CD13 (91%), CD33 (54.8%), CD34 (94.5%), and HLA-DR (97.9%). Some leukemic cells (15.6%) also expressed CD14. Cytogenetic analysis revealed 92,XXYY,t(9;22)(q34;q11)x2 in all 20 metaphase cells. Reverse transcriptase polymerase chain reaction analysis detected the minor BCR/ABL messenger RNA (mRNA) but failed to detect the major BCR/ABL mRNA. The patient achieved complete remission after induction chemotherapy, with no evidence of Philadelphia chromosome (Ph) or minor BCR/ABL mRNA. Ph-positive acute myeloid leukemia (Ph-AML) has rarely been reported. Herein, we report a case of Ph-AML with tetraploidy and review the previously reported Ph-AML cases.
authors.affiliation: Department of Internal Medicine, Nippon Medical School, Tokyo, Japan.
authors.forename: Hiroki
authors.initials: H
authors.lastname: Yamaguchi
authors.forename: Koiti
authors.initials: K
authors.lastname: Inokuchi
authors.forename: Ena
authors.initials: E
authors.lastname: Yokomizo
authors.forename: Junko
authors.initials: J
authors.lastname: Miyata
authors.forename: Ayako
authors.initials: A
authors.lastname: Watanabe
authors.forename: Mituharu
authors.initials: M
authors.lastname: Inami
authors.forename: Kenji
authors.initials: K
authors.lastname: Tajika
authors.forename: Kazuo
authors.initials: K
authors.lastname: Dan
mesh_terms: D000208:Acute Disease; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use; D014408:Biomarkers, Tumor / Q000235:genetics; D003561:Cytarabine / Q000008:administration & dosage / Q000031:analogs & derivatives*; D003630:Daunorubicin / Q000008:administration & dosage; D016044:Fusion Proteins, bcr-abl / Q000235:genetics; D006801:Humans; D007621:Karyotyping; D015464:Leukemia, Myelogenous, Chronic, BCR-ABL Positive / Q000235:genetics*; D008297:Male; D015122:Mercaptopurine / Q000008:administration & dosage; D008875:Middle Aged; D008942:Mitoxantrone / Q000008:administration & dosage; D011123:Polyploidy; D011239:Prednisolone / Q000008:administration & dosage; D012333:RNA, Messenger / Q000235:genetics; D012334:RNA, Neoplasm / Q000235:genetics; D012074:Remission Induction
chemical_list: D014408:Biomarkers, Tumor; D012333:RNA, Messenger; D012334:RNA, Neoplasm; D003561:Cytarabine; D011239:Prednisolone; C015019:enocitabine; D008942:Mitoxantrone; D015122:Mercaptopurine; D016044:Fusion Proteins, bcr-abl; D003630:Daunorubicin